GlycoMimetics scales down IPO to $46M; Isarna raises $18M for cancer R&D; Aldexa files $20M IPO;

@FierceBiotech: Texas' Bellicum gets $15M to expand work on gene 'switch' tech. More | Follow @FierceBiotech

@JohnCFierce: In search for success, R&D teams are overcrowding small drug franchises. Story | Follow @JohnCFierce

@DamianFierce: Friendly reminder that there were 27 drugs approved last year and we wrote, like, 1,000 words on each. Report | Follow @DamianFierce

@EmilyMFierce: Alcohol-addicted rats treated with optogenetics stop drinking. More from FierceBiotech Research | Follow @EmilyMFierce

> In a renewed effort to go public, GlycoMimetics says it will sell 5.8 million shares at $8 each. The IPO is now designed to raise about $46 million. Story

> Germany's Isarna Therapeutics has raised close to $18 million in venture cash. The biotech says it plans to use the money on its "pipeline of next generation oligonucleotides that inhibit various isoforms of TGF-β, a key molecular pathway implicated in mechanisms used by cancer cells to evade immune system detection and to aid in tumor proliferation." Release

> Burlington, MA-based Aldexa Therapeutics filed for a $20 million IPO. The biotech is studying new therapies for rare diseases. Filing

Medical Device News

@FierceMedDev: BD trades $40M for diagnostics partner Alverix. More | Follow @FierceMedDev

@MichaelGFierce: How a single nanoparticle delivers two drugs separately to kill cancer cells. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: The FDA warns Abbott's faulty blood glucose test strips could lead to serious injury or death. Story | Follow @GalenMoore

> Sapheon hauls in $10M as it works toward FDA approval for a varicose vein device. Item

> Stryker teams with Samsung's NeuroLogica on a portable CT scanner. More

> FDA slaps its most serious label on Abbott's diabetes recall. Article

> Medtronic spends $160M on Tyrx and its antibacterial envelopes. News

Pharma News

@FiercePharma: Move over, BigPharma. Valeant's CEO plans to elbow his way in. More | Follow @FiercePharma

@EricPFierce: China clears vaccinemakers in deaths then shuts some down. Story | Follow @EricPFierce

@CarlyHFierce: Hi-Tech Pharmacal CEO to reap almost $85M from its sale to Akorn. Article | Follow @CarlyHFierce

> Just as hep C star Sovaldi makes its debut, Gilead commercial chief says he'll retire. More

> Lilly admits 2014 sales won't hit $20B, but sticks to $3B profits target. News

Biotech Research News

> Cancer Research UK will repurpose an AstraZeneca asthma drug for kidney cancer. More

> 6 U.S. institutions receive $540M in cancer research funds. Story

> Astellas, ClearPath team up to develop vaccines for infectious diseases. Article

> Gene defect that blocks insulin release in mice may cause Type 2 diabetes. News

> Alcohol-addicted rats treated with optogenetics stop drinking. Report

> Discovery of immune boosters' role in TB control could help develop new therapeutics. Item

Pharma Manufacturing News

> $1B deal pushes GE further into biologics manufacturing. More

> Pall moves into single-use bioreactors with deal to buy ATMI LifeSciences. Article

> Chinese heparin maker Hepalink buying U.S.-based SPL. Story

> China clears vaccine makers in deaths then shuts some down. News

> EMA makes inspection reports public. Item

> Baxter issues another recall after particulate found in products. Report

 

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.